Aleafia Health Past Earnings Performance
Past criteria checks 0/6
Aleafia Health's earnings have been declining at an average annual rate of -30%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 37.2% per year.
Key information
-30.0%
Earnings growth rate
-18.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 37.2% |
| Return on equity | n/a |
| Net Margin | -80.8% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aleafia Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 43 | -35 | 20 | 0 |
| 31 Dec 22 | 38 | -12 | 20 | 0 |
| 30 Sep 22 | 36 | -58 | 23 | 0 |
| 30 Jun 22 | 36 | -146 | 25 | 0 |
| 31 Mar 22 | 34 | -136 | 31 | 0 |
| 31 Dec 21 | 36 | -166 | 46 | 0 |
| 30 Sep 21 | 43 | -312 | 48 | 0 |
| 30 Jun 21 | 38 | -248 | 45 | 0 |
| 31 Mar 21 | 37 | -252 | 35 | 0 |
| 31 Dec 20 | 36 | -256 | 29 | 0 |
| 30 Sep 20 | 35 | -40 | 22 | 0 |
| 30 Jun 20 | 35 | -18 | 27 | 0 |
| 31 Mar 20 | 29 | -26 | 26 | 0 |
| 31 Dec 19 | 16 | -40 | 39 | 0 |
| 30 Sep 19 | 11 | -42 | 49 | 0 |
| 30 Jun 19 | 7 | -47 | 44 | 0 |
| 31 Mar 19 | 5 | -37 | 38 | 0 |
| 31 Dec 18 | 3 | -19 | 20 | 0 |
| 30 Sep 18 | 3 | -8 | 10 | 0 |
| 30 Jun 18 | 1 | -5 | 6 | 0 |
| 31 Mar 18 | 0 | -4 | 4 | 0 |
| 31 Dec 17 | 0 | -11 | 11 | 0 |
Quality Earnings: ALEA.F is currently unprofitable.
Growing Profit Margin: ALEA.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALEA.F is unprofitable, and losses have increased over the past 5 years at a rate of 30% per year.
Accelerating Growth: Unable to compare ALEA.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALEA.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: ALEA.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.